Smart insulin pump could transform hospital diabetes care
NCT ID NCT07645079
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial compares an automated insulin delivery system (AID) to standard insulin injections for managing blood sugar in hospitalized adults with type 2 diabetes who have an infection. The AID system uses a continuous glucose monitor and a smart pump to automatically adjust insulin. The study aims to see if the AID system keeps blood sugar in a healthy range better than usual care. Participants are randomly assigned to either the AID system or standard insulin therapy, and their blood sugar levels are tracked throughout their hospital stay.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
automated insulin delivery system (mylife YpsoPump with FreeStyle Libre 3 sensor)
What this could lead to
If successful, this could show that automated insulin delivery is safer and more effective than standard care for managing blood sugar in hospitalized patients with type 2 diabetes.
What could go wrong
This is a relatively small trial (92 participants) and results may not apply to all hospitals or patient groups. The device may not work as well in sicker patients or could have technical issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Steno Diabetes Center Copenhagen
Copenhagen, 2730, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital of Graz
Graz, Styria, 8036, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••